The Use of Recombinant DNA :: Papers

The Use of Recombinant DNA I agree that recombinant DNA benefits humans only to a certain extent though. During the late sixties and early 1970s a series of independent discoveries made in rapid succession yielded a new technology whereby humans have the cogency to manipulate and direct the very evolution of life itself. This is accomplished through the forge of gene splicing (Recombinant DNA). There are four essential elements of the process a method of breaking and joining DNA molecules from different sources, a gene carrier that can replicate both itself and the foreign DNA, a meat of introducing the foreign DNA into a functional bacteria cell, and a method of selecting from a large population the cells which carry the foreign DNA. Using procedures like recombinant DNA, many an(prenominal) human genes have been cloned in E. coli or in yeast. This was made possible for the first time to produce unlimited amounts of human proteins. Cultured cells (E. coli, yeast, mammalian cells) alter with the human gene are being consumptiond to manufacture insulin for diabetics, human growth hormone (GH) GH from domestic mammals like cows and pigs does not work in humans. So for many years, the only source of GH for therapy was that taken out from the glands of human cadavers. But this supply was shut off when several patients died from a rare neurological disease attributed to contaminated glands. Now, thanks to recombinant DNA technology, recombinant human GH is available. While a great benefit to patients suffering form GH deficiency, there has also been pressure to use it to stimulate growth in youngsters who have no deficiency but whose parents want them to grow up tall, erythropoietin (EPO) People with failing kidneys can be unplowed alive by dialysis. But dialysis only cleanses the blood of wastes. Without a source of EPO, these patients suffer from anaemia. Now, thanks to recombinant DNA technology, r ecombinant human EPO is available to treat these patients, for treating anaemia, tissue plasminogen activator (TPA) for profligacy blood clots, angiostatin and endostatin for trials as anti-cancer